BPC
ANIP icon

Bryce Point Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Bryce Point Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,472
Closed -$292K – 175
2025
Q2 		$292K Buy
+4,472
New +$291K 0.25% 149

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bryce Point Capital's ANIP Position: Q3 2025 in Review

Bryce Point Capital sold out of ANI Pharmaceuticals (ANIP) in Q3 2025, closing a stake of 4,472 shares — an estimated $292K sold.

Bryce Point Capital first reported a position in ANIP in Q2 2025 and held it in 1 quarter. The position peaked at $292K in Q2 2025. 269 funds tracked by Wall St. Rank hold ANIP as of Q3 2025.

  • Bryce Point Capital reported no remaining ANI Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Bryce Point Capital sold 4,472 ANI Pharmaceuticals shares in Q3 2025, an estimated $292K.
  • Bryce Point Capital first reported a position in ANI Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Bryce Point Capital's ANI Pharmaceuticals position peaked at $292K in Q2 2025.
  • 269 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.